Can-Fite BioPharma Ltd. (CANF)
USD 1.36
(-3.55%)
USD 1.36
(-3.55%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.98 Million USD | 7.61% |
| 2022 | 9.28 Million USD | -54.16% |
| 2021 | 20.25 Million USD | 112.67% |
| 2020 | 9.52 Million USD | 16.5% |
| 2019 | 8.17 Million USD | 2.79% |
| 2018 | 7.95 Million USD | 1.53% |
| 2017 | 7.83 Million USD | -22.96% |
| 2016 | 10.16 Million USD | -42.24% |
| 2015 | 17.6 Million USD | 72.78% |
| 2014 | 10.18 Million USD | 53.54% |
| 2013 | 6.63 Million USD | 305.74% |
| 2012 | 1.63 Million USD | -66.65% |
| 2011 | 4.9 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 5.92 Million USD | 0.0% |
| 2024 Q1 | 5.92 Million USD | -40.71% |
| 2023 Q4 | 9.98 Million USD | 8.94% |
| 2023 FY | 9.98 Million USD | 7.61% |
| 2023 Q1 | 13.48 Million USD | 45.31% |
| 2023 Q2 | 11.03 Million USD | -18.21% |
| 2023 Q3 | 9.16 Million USD | -16.89% |
| 2022 Q1 | 17.84 Million USD | -11.88% |
| 2022 Q4 | 9.28 Million USD | -26.94% |
| 2022 Q3 | 12.7 Million USD | -13.83% |
| 2022 FY | 9.28 Million USD | -54.16% |
| 2022 Q2 | 14.74 Million USD | -17.38% |
| 2021 Q1 | 12.74 Million USD | 33.8% |
| 2021 Q4 | 20.25 Million USD | 38.35% |
| 2021 Q3 | 14.63 Million USD | 51.23% |
| 2021 Q2 | 9.68 Million USD | -24.03% |
| 2021 FY | 20.25 Million USD | 112.67% |
| 2020 Q1 | 9.84 Million USD | 20.46% |
| 2020 Q2 | 12.8 Million USD | 29.98% |
| 2020 FY | 9.52 Million USD | 16.5% |
| 2020 Q3 | 13.32 Million USD | 4.11% |
| 2020 Q4 | 9.52 Million USD | -28.54% |
| 2019 Q1 | 7.48 Million USD | -5.82% |
| 2019 Q4 | 8.17 Million USD | -30.43% |
| 2019 Q2 | 13.66 Million USD | 82.49% |
| 2019 Q3 | 11.75 Million USD | -14.02% |
| 2019 FY | 8.17 Million USD | 2.79% |
| 2018 FY | 7.95 Million USD | 1.53% |
| 2018 Q4 | 7.95 Million USD | -26.54% |
| 2018 Q3 | 10.82 Million USD | -1.45% |
| 2018 Q2 | 10.98 Million USD | -11.95% |
| 2018 Q1 | 12.47 Million USD | 59.28% |
| 2017 Q3 | 8.76 Million USD | -14.78% |
| 2017 Q2 | 10.29 Million USD | -16.07% |
| 2017 Q1 | 12.26 Million USD | 20.58% |
| 2017 FY | 7.83 Million USD | -22.96% |
| 2017 Q4 | 7.83 Million USD | -10.68% |
| 2016 FY | 10.16 Million USD | -42.24% |
| 2016 Q2 | 13.82 Million USD | -15.87% |
| 2016 Q4 | 10.16 Million USD | -13.99% |
| 2016 Q1 | 16.42 Million USD | -6.67% |
| 2016 Q3 | 11.82 Million USD | -14.47% |
| 2015 Q3 | 15.21 Million USD | 77.86% |
| 2015 Q2 | 8.55 Million USD | -14.21% |
| 2015 Q1 | 9.96 Million USD | -2.13% |
| 2015 Q4 | 17.6 Million USD | 15.71% |
| 2015 FY | 17.6 Million USD | 72.78% |
| 2014 Q1 | 8.72 Million USD | 31.57% |
| 2014 Q4 | 10.18 Million USD | 109.37% |
| 2014 Q3 | 4.86 Million USD | -24.36% |
| 2014 FY | 10.18 Million USD | 53.54% |
| 2014 Q2 | 6.43 Million USD | -26.31% |
| 2013 Q2 | 4.59 Million USD | -22.42% |
| 2013 Q3 | 3.2 Million USD | -30.21% |
| 2013 Q1 | 5.92 Million USD | 262.28% |
| 2013 FY | 6.63 Million USD | 305.74% |
| 2013 Q4 | 6.63 Million USD | 106.83% |
| 2012 Q1 | 3.7 Million USD | -24.37% |
| 2012 Q3 | 2.54 Million USD | -27.15% |
| 2012 Q4 | 1.63 Million USD | -35.68% |
| 2012 Q2 | 3.48 Million USD | -5.88% |
| 2012 FY | 1.63 Million USD | -66.65% |
| 2011 FY | 4.9 Million USD | 0.0% |
| 2011 Q4 | 4.9 Million USD | 254.78% |
| 2011 Q3 | 1.38 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | 48.46% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -74.146% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 90.916% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 87.735% |
| Azitra, Inc. | 5.11 Million USD | -95.27% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -10263.001% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | 0.299% |
| CEL-SCI Corporation | 30.52 Million USD | 67.279% |
| iBio, Inc. | 28.73 Million USD | 65.236% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 90.112% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | -32.01% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | 84.768% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -128.497% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | -10.571% |
| NanoViricides, Inc. | 12.82 Million USD | 22.1% |
| Oragenics, Inc. | 4.96 Million USD | -101.134% |
| BiomX Inc. | 58.15 Million USD | 82.824% |
| BiomX Inc. | 58.15 Million USD | 82.824% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | 88.169% |
| Palatin Technologies, Inc. | 10.74 Million USD | 7.012% |
| Scorpius Holdings, Inc. | 51.03 Million USD | 80.428% |
| Theriva Biologics, Inc. | 60.21 Million USD | 83.41% |